Neurocognitive function and quality of life results from a phase II study (NRG/RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas.
- DOI
- 10.1016/j.ijrobp.2026.10.031
- Published
- 2026 Nov 8
- Container
- International journal of radiation oncology, biology, physics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ijrobp.2026.10.031,
title = {Neurocognitive function and quality of life results from a phase II study (NRG/RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas.},
author = {Wefel JS and Pugh SL and Choucair AK and Fisher BJ and Rogers CL and Mikkelsen T and Glass J and Yu HM and Robins HI and Won M and Mehta MP and Movsas B},
year = {2026},
journal = {International journal of radiation oncology, biology, physics},
doi = {10.1016/j.ijrobp.2026.10.031},
url = {https://doi.org/10.1016/j.ijrobp.2026.10.031}
}RIS
TY - JOUR TI - Neurocognitive function and quality of life results from a phase II study (NRG/RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas. AU - Wefel JS AU - Pugh SL AU - Choucair AK AU - Fisher BJ AU - Rogers CL AU - Mikkelsen T AU - Glass J AU - Yu HM AU - Robins HI AU - Won M AU - Mehta MP AU - Movsas B PY - 2026 JO - International journal of radiation oncology, biology, physics DO - 10.1016/j.ijrobp.2026.10.031 UR - https://doi.org/10.1016/j.ijrobp.2026.10.031 ER -
APA
JS, W., SL, P., AK, C., BJ, F., CL, R., T, M., J, G., HM, Y., HI, R., M, W., MP, M., & B, M. (2026). Neurocognitive function and quality of life results from a phase II study (NRG/RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas.. International journal of radiation oncology, biology, physics. https://doi.org/10.1016/j.ijrobp.2026.10.031
Source records
- pubmed · retrieved 2026-11-10T05:02:46.350Z